Clinical Trial Detail

NCT ID NCT03202316
Title Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

inflammatory breast carcinoma

Therapies

Atezolizumab + Cobimetinib + Eribulin

Age Groups: adult senior

No variant requirements are available.